Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study

Atea Pharmaceuticals (AVIR) announced that the first patient has been dosed in C-BEYOND, Atea’s Phase 3 trial evaluating the regimen of bemnifosbuvir and ruzasvir for the treatment of adults with chronic hepatitis C virus. C-BEYOND is an open-label trial being conducted in the US and Canada comparing the combination regimen of bemnifosbuvir and ruzasvir to the combination regimen of sofosbuvir and velpatasvir. The regimen of bemnifosbuvir and ruzasvir will be administered orally once-daily for 8 weeks or 12 weeks while the regimen of sofosbuvir and velpatasvir will be administered orally once-daily for 12 weeks.